
Dx Deals: Quest Diagnostics M&A Centers on Precision-Focused Approach
Recent inroads into testing of water for dialysis equipment illustrates Quest’s expanded scope with deals
Recent inroads into testing of water for dialysis equipment illustrates Quest’s expanded scope with deals
Becton Dickinson divisions responsible for $3.4 billion in annual revenue are on the block
The rounds of funding to Clarapath, PreciseDx, and Precision Epigenomics come at a time when other M&A activity is seasonally slow
The roughly $1 billion deal will boost the company’s annual revenue by about 7 percent, and will give Quest a stronger presence in Canada
Deal is expected to give the lab giant a big boost in deploying artificial intelligence in the pathology space.